Oncolytics Logo
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

Investor Center
Corporate Governance

  • Investor Center
  • Corporate Governance

Oncolytics Biotech Inc. believes in a transparent and forward-facing approach to business.

Committee Charters

Board of Directors Mandate
Audit Committee Mandate
Compensation Committee Mandate
Corporate Governance Committee Mandate
Science and Technology Committee Mandate


Governance Documents

Code of Ethics for CEO, CFO and Accounting Officers
Employee Code of Ethics
Corporate Trading Policy
Policy on Trading and Confidential Information
Policy Regarding Accounting and Auditing Matters

 

Investor Center

  • Investor Overview
  • Stock Information
  • Financials
  • Presentations
  • Corporate Governance
  • RSS Feeds
  • Analyst Coverage

Latest News

December 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

December 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer

December 4, 2017

Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

View All News
  • News
Dec 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Dec 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles
Aug 9, 2016

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

@Oncolytics Feb 23, 2021

Data from a Mayo study show pelareorep demonstrated the potential to broaden the applicability of CAR T cells to so… https://t.co/ausWexcm4f

@Oncolytics Feb 4, 2021

Learn how pelareorep works with immunotherapies in this brief clip, a full length version of this video can be foun… https://t.co/UqCHYemBKi

Follow us on Twitter
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

Sign up to receive email updates

Sign Up
Linkedin Icon
  • Privacy | Legal Notice
Copyright © Oncolytics Biotech® Inc. 2021 All rights reserved

Site by
Site by Pace Creative Alberta Site by Pace Creative Alberta